(Q37391070)

20 August 2017

0 references

1 reference

title

Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials (English)

1 reference

20 August 2017

0 references

0 references

1 reference

1 reference

1 reference

3

Leonard Leibovici

1 reference

20 August 2017

2

Anat Gafter-Gvili

1 reference

20 August 2017

8

Ofer Shpilberg

1 reference

20 August 2017

Liat Vidal

1

1 reference

20 August 2017

Martin Dreyling

4

1 reference

20 August 2017

Michele Ghielmini

5

1 reference

20 August 2017

Shu-Fang Hsu Schmitz

6

1 reference

20 August 2017

Amos Cohen

7

1 reference

20 August 2017

language of work or name

English

0 references

publication date

10 February 2009

1 reference

Journal of the National Cancer Institute

20 August 2017

1 reference

20 August 2017

101

1 reference

20 August 2017

4

1 reference

20 August 2017

248-255

1 reference

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

20 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Randomized trials stopped early for benefit: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Systematic reviewers neglect bias that results from trials stopped early for benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN478

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN478

1 reference

20 August 2017

1 reference